Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, March 7, 2014, 162 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $252.67 to $79,694,022.59.

Highlighted Stocks Traded by Insiders:

ACADIA Pharmaceuticals (ACAD) - FREE Research Report

Baker Bros. Advisors Lp who is Director at ACADIA Pharmaceuticals bought 526,316 shares at $28.50 on March 7, 2014. Following this transaction, the Director owned 452,540 shares meaning that the stake was reduced by 713.4% with the 526,316-share transaction.

The shares most recently traded at $27.76, down $0.74, or 2.67% since the insider transaction.

The average volume for ACADIA Pharmaceuticals has been 1.6 million shares per day over the past 30 days. ACADIA Pharmaceuticals has a market cap of $2.5 billion and is part of the health care sector and drugs industry. Shares are up 8.72% year-to-date as of the close of trading on Friday.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. Currently there are 6 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACAD - FREE

TheStreet Quant Ratings rates ACADIA Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. Get the full ACADIA Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon